A filing with the US Securities and Exchange Commission (SEC) reveals details of Kyverna Therapeutics’ bid to tap into an increasingly favorable market for init 2 February 2024
Chicagoan biotech COUR Pharmaceuticals has raised $105 million in a series A financing round, co-led by Lumira Ventures and Alpha Wave Ventures. 31 January 2024
Enterprise Therapeutics, a UK biopharma dedicated to the discovery and development of novel therapies for respiratory disease, has closed a £26 million ($33.1 m 30 January 2024
Industry observers are cautiously hoping that early 2024 signs indicate that the post-pandemic biotech fundraising slowdown might be coming to and end. 30 January 2024
Earlier this week, ArriVent Biopharma filed for an IPO, following several other young biotechs giving notice they planned to take the plunge in 2024. 25 January 2024
Accent Therapeutics, a US biopharma seeking to develop a new class of small molecule precision cancer therapies, has announced the completion of a $75 million S 23 January 2024
Small biotechs continue to show more interest in a public listing in 2024, with ArriVent Biopharma the latest to opt for an initial public offering (IPO) in the 23 January 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.